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ABSTRACT 
 
The Pathogenesis of Cache Valley Virus in the Ovine Fetus. (December 2011) 
Aline Rodrigues, D.V.M.; M.S., Universidade Federal de Santa Maria 
Co-Chairs of Advisory Committee: Dr. John F. Edwards 
                     Dr. Christabel Jane Welsh 
 
 Cache Valley virus (CVV) induced malformations have been previously 
reproduced in ovine fetuses; however, no studies have established the CVV infection 
sequence of the cells targeted by the virus or the development of the antiviral response of 
the early, infected fetus that results in viral clearance before development of 
immunocompetency. To address these questions, ovine fetuses at 35 dg were inoculated 
in utero with CVV and euthanized at 7, 10, 14, 21 and 28 dpi. On postmortem 
examination arthrogryposis and oligohydramnios were observed in some infected 
fetuses. Morphologic studies showed necrosis in the central nervous system (CNS) and 
skeletal muscle of earlier infected fetuses and hydrocephalus, micromyelia and muscular 
loss in later infected fetuses. Using immunohistochemistry and in situ hybridization, 
intense CVV viral antigenic signal was detected in the brain, spinal cord, skeletal 
muscles and fetal membranes of infected fetuses. Viral signal decreased in targeted and 
infected tissues with the progression of the infection.  
To determine specific cell types targeted by CVV in the CNS, indirect 
immunofluorescence was applied to sections of the CNS using a double labeling 
technique with antibodies against CVV together with antibodies against neurons, 
  
 
iv 
astrocytes and microglia. CVV viral antigen was shown within the cytoplasm of neurons 
in the brain and spinal cord. No viral signal was observed in microglial cells; however, 
infected animals had marked microgliosis. 
The antiviral immune response in immature fetuses infected with CVV was 
evaluated. Gene expression associated with an innate, immune response was quantified 
by real-time, quantitative PCR. Upregulated genes in infected fetuses included ISG15, 
Mx1, Mx2, IL-1, IL-6, TNF-α, TLR-7 and TLR-8. The amount of Mx protein, an 
interferon stimulated GTPase capable of restricting growth of bunyaviruses, was 
elevated in the allantoic and amniotic fluid in infected fetuses. ISG15 protein expression 
was significantly increased in target tissues of infected animals. B lymphocytes and 
immunoglobulin-positive cells were detected in lymphoid tissues and in the meninges of 
infected animals. This demonstrated that the infected ovine fetus is able to stimulate an 
innate and adaptive immune response before immunocompetency that presumably 
contributes to viral clearance in infected animals.   
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NOMENCLATURE 
 
BRA  Brain 
BVDV Bovine viral diarrhea virus 
CNS Central nervous system 
CPE Cytopathic effect 
CVV Cache Valley virus 
DG days of gestation 
DPI days post infection  
H&E Hematoxylin and eosin 
IHC Immunohistochemistry 
ISG Interferon stimulated gene 
ISH In situ hybridization 
MEM Minimal essential medium 
MSS Musculoskeletal system 
Mx Myxovirus resistance factor 
PAMP Pathogen associated molecular pattern 
qPCR quantitative polymerase chain reaction 
SKM Skeletal muscle 
SPC Spinal cord 
TCID50 50% Tissue culture infection doses 
TLR Toll like receptor 
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CHAPTER I  
INTRODUCTION, SIGNIFICANCE AND LITERATURE REVIEW 
 
Significance 
 
Fetal loss and abortions are common problems in the livestock industry. 
Frequently caused by genetic defects, toxins, hormonal imbalances and infectious 
agents, they are responsible for significant economic loss.
34
 CVV is an infectious agent 
that causes abortion and fetal malformations in sheep and infrequently in other 
ruminants. Occasionally, CVV causes outbreaks of fetal losses.
29-31,39,44
 Serologic 
surveys have shown that CVV is endemic in United States and infects many, large 
mammalian species.
16,20,22,31,39,57,95,96,103,122
 Both single cases and outbreaks of fetal loss 
and malformations have been described in sheep,
29-31,39
 goats
40
 and occasionally cattle in 
Texas
33
 and many states (most recently in Kansas,
45
 with anecdotal reports from North 
Dakota
119
 and South Dakota).
67
 
As this disease can affect reproductive performance in ruminants in the United 
States, it is important to understand the pathogenesis of this virus, the progression of the 
infection and the development of an immune response in infected ruminant fetuses. This  
 
 
 
___________ 
This dissertation follows the style of Veterinary Pathology. 
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data could further contribute to understanding of disease pathogenesis and could spur 
development of new diagnostic techniques to detect infected animals.  Because this 
infectious agent is associated with rare cases of human encephalitis,
25,128
 understanding 
the pathogenesis of CVV infection may be relevant to the study of fetal malformations 
caused by viruses in humans.
23
 
 
The organism 
 
CVV belongs to the family Bunyaviridae, Orthobunyavirus genus, Bunyamwera 
group. This family contains more than 250 viruses distributed in five genera, four of 
which, Orthobunyavirus, Nairovirus, Phlebovirus and Hantavirus, are recognized to 
infect mammals, and one, Tospovirus, that infects plants.
127
 With the exception of the 
hantaviruses that are transmitted by rodent secretions, most of the Bunyaviridae are 
transmitted by arthropods. The viruses within the Orthobunyavirus genus are transmitted 
by mosquitoes. The genus includes several viruses that cause disease and encephalitis in 
humans, including the viruses of the California group, such as California encephalitis 
virus, La Crosse virus, Jamestown Canyon virus and Snowshoe hare virus. In addition,  
two members of the Simbu group are considered significant pathogens of domestic 
animals, Akabane virus, which causes abortions and fetal malformations in 
ruminants,
11,126,127
 similar to the disease caused by CVV, and Aino virus, which has been 
serologically implicated as causing congenital defects in calves and lambs.
109
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The virions in this family are 80 to 120 nm in diameter and primarily spherical 
with glycoprotein projections embedded in the envelope lipid bilayer. The viral genome 
is composed of three, single-stranded RNA segments, large (L), medium (M) and small 
(S). These segments are complexed with the nucleocapsid protein to form individual L, 
M, and S ribonucleocapsids. A virion-associated polymerase of unknown specific 
location is necessary to copy the negative-sense, viral genome into positive-sense, 
messenger RNA found in virions. In most cases, bunyaviruses use only a negative–sense 
coding strategy; however, some bunyaviruses use a combination of a negative-sense and 
ambi-sense coding strategy when coding the S and M segments. The S segment of the 
Orthobunyavirus genus members encodes the nucleocapsid protein and the nonstructural 
protein in overlapping reading frames
98
 within the same cRNA. The M segment encodes 
two envelope glycoproteins in a single open reading frame (ORF). A single, large ORF 
is used to encode the L segment of the L protein that functions as the viral 
polymerase.
11,14,126,127
    
Briefly, the replication process of bunyaviruses is as follows:
126,127
 
1. Attachment (interaction of viral proteins and host receptors); 
2. Entry, mediated by endocytosis; 
3. Uncoating in acidic endocytic vesicles, and viral membrane fusion with 
endosomal membranes; 
4. Transcription of viral mRNA through a virion-associated polymerase (using 
host cell-derived primers); 
5. Translation of mRNA (L, M, S); 
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6. RNA replication, membrane-associated (synthesis of cRNA, that serves as 
template for cRNA); 
7. Transport to golgi, assembly and glycosylation; 
8. Migration of golgi vesicles and fusion with the plasma membrane and 
subsequent release of mature virions. 
Bunyaviruses cause cytopathic effect in cultured cells and are generally cytolytic 
for targeted cells in vertebrate hosts. However, in invertebrate hosts, little or no cytolysis 
is observed in cells and tissues. The vertebrate host cell responds to infection by 
triggering interferon pathways, such as those of type 1 interferon, that result in activation 
of regulatory signals and an antiviral state in the infected cells.
60,97,116
 Another 
mechanism used by the host cells to control the infection and degrade specific viral 
mRNA sequences is the synthesis of small, interfering RNAs from the cleavage of 
double stranded RNA.
111,127,136
  The viruses, however, try to prevent activation of the 
interferon pathway at the level of cellular transcription.
78,149
 Bunyaviruses also have 
been demonstrated to inhibit the host cell machinery by inhibiting protein synthesis and 
activation of caspases leading to cellular apoptosis.
126,127,1,12,32,111
  
 
Bunyavirus pathogenesis 
 
According to the tissue tropism of orthobunyaviruses, the clinical disease in 
infected hosts can be simplistically divided into two forms: infantile and adult infection 
with encephalitis, and placental and fetal infection with malformations and fetal death. 
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In both forms, the virus is introduced into the bloodstream by an insect vector during a 
blood meal. The first round of replication occurs within the cells in the superficial 
dermis and is followed by spread of the virus to target organs.  Infection results in 
invasion of the central nervous system (CNS) or, in ruminants, in transplacental 
infection of the fetus.
109
 
Members of the Bunyamwera group may cause a relatively mild infection in adult 
hosts, despite rare cases of encephalitis described in some hosts during spontaneous and 
experimental human infections.
109,137
 Members of the California group cause severe 
encephalitis in children. Experimental studies with viruses in the California group have 
demonstrated that after subcutaneous inoculation, the virus replicates in smooth muscle 
cells of blood vessels and later enter the reticulo-endothelial system with a short 1-3 day 
viremia. After primary viremia, the viruses cross the blood-brain barrier with active viral 
replication occurring in endothelial cells.
72,109
 Ability of the virus to invade the CNS to 
cause severe disease (meningitis, meningoencephalitis or encephalitis) presumably 
depends on the age of the host and the virus strain or serotype.   
Experimental studies in pregnant ewes infected with Akabane virus in the Simbu 
group, have shown that after intravenous inoculation, the virus invades placental tissues 
within 1 day and the fetal tissues within 5-7 days after inoculation.
109,110
 Experimentally 
infected ewes develop a short viremia with development of serum neutralizing 
antibodies independent of the route of inoculation (subcutaneous, intravenous or 
intrauterine).
105,108-110
 The development of lesions in the fetus will depend on the stage of 
fetal development when infected. If infection occurs before immunocompetency, 
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Akabane virus can cause severe necrosis in developing fetal tissues, including fetal 
brain, skeletal muscle, trophoblasts and placental membrane epithelium. If the fetus 
survives the infection musculoskeletal system (MSS) and CNS malformations 
occur.
26,106
  
 
Cache Valley Virus 
 
CVV was first described and isolated from a Culiseta inornata mosquito pool 
collected in 1956 in Cache Valley, Utah, an like other Bunyavirus, CVV caused 
encephalitis when inoculated intracerebrally into newborn mice.
69
 Since then, CVV has 
been isolated from several mosquito genera, including Aedes, Anopheles, Psorophora, 
Coquilettidia and Culex, from numerous states in the USA,
15,21,22,39,65,79,90,95,96,123
 
Canada
57,71
 and in other countries in the Americas.
3,13,20,38,49,152,154
 Although unproven, 
Culiseta inornata is considered the principal vector of CVV.
65
 As with most arboviruses, 
it is believed that effector molecules in mosquito saliva enhance CVV transmission and 
infection.
42
  
CVV naturally infects a wide variety of animal species, and serologic and/or 
virologic evidence of infection has been described in sheep,
29-31,39,43,44
 cattle,
122,153
 
horses,
24,79,96
 deer,
16,103
 goat,
40
 pig, raccoons, woodchuck,
20
 caribou, turtles,
21
 rabbits
2,17
 
and foxes.
98
 Serologic evidence of human infection with rare cases of 
meningoencephalitis are also described.
25,128,23,41,93,142,148
 
  
7 
7
 
In sheep, CVV is responsible for embryonic and fetal death, stillbirths and 
congenital malformations including hydrocephalus, hydranencephaly, microencephaly, 
porencephaly, torticollis, scoliosis, arthrogryposis, oligoamnion and flexural 
deformities.
29,30,34,39,44
 In adult sheep, the infection is usually subclinical.
34,39
  
The fetal disease can be experimentally reproduced in sheep by intrauterine 
inoculation of CVV. Reproducing fetal infection has proved itself to be difficult when 
CVV is inoculated intravenously into pregnant sheep.
30,34,39
 Experimental infection in 
pregnant ewes can result in fever, depression and innapetence.
30,39
 Similar to Akabane 
virus infection,
102
 the ovine fetus is susceptible to development of fetal malformations if 
CVV is inoculated between 28 and 48 days of gestation (dg). Embryonic death and 
mummification occur if the virus is inoculated before 28 dg. If the virus is inoculated 
after 48 dg, no malformations are observed.
30,39
 In Akabane virus-infected fetuses, virus 
can be identified in placentomes 24 hours after infection, indicating that this may be the 
portal of infection of the fetus.
110
 The infection of the fetal membranes with CVV can 
cause oligohydramnios and oligohydroallantois, possibly resulting in fetal akinesia that 
could contribute to development of arthrogryposis.
39
 In experimental infections, the 
virus is cleared from the tissues of infected fetuses within 4 to 6 weeks after infection.
94
  
 Serum neutralization is the most commonly used test to identify viral exposure. 
Because no transfer of maternal antibodies to fetuses occurs in utero, the identification 
of viral neutralizing antibodies in precolostral heart blood implies in utero exposure and 
infection. Virus isolation from blood can be used to identify infected animals; however, 
the viremia in adult sheep is short. Virus can be isolated from tissues of early infected 
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fetuses, but viral recovery from term fetuses is unlikely, because the virus is cleared 
from tissues within a few weeks after infection.
34,39
 Polymerase chain reaction (PCR) has 
been used to identify RNA from CVV in infected cell cultures and tissues from infected 
animals and humans.
18,19,25,34,128
 
Experimental infection of CVV in mice does not result in infection or antibody 
production if the virus or the virus with the vector saliva is inoculated subcutaneously. 
Infection and antibody production occurred only into sites that had been previously fed 
by mosquitoes. In the same study, CVV infection in pregnant mice did not result in fetal 
death or malformations in pups.
42
 
 
Ovine fetal immune system development 
 
The gestation period of the ewe is approximately 145 days. In the ovine fetus, the 
development of erythropoiesis, myelopoiesis and megakaryopoiesis occurs in the yolk 
sac and liver at approximately 17 dg.
99
 Cells expressing MHC class I and MHC class II 
can be identified by 19 and 25 dg, respectively.
145
 At approximately 20 to 25 dg, 
lymphocyte production begins in the thymus. At 48-50 dg, lymphocytes are seen in the 
bloodstream.  At 55-60 dg, lymphocytes are found in spleen and lymph nodes. At 75-80 
dg, they are in the bone marrow and Peyer’s patches. By 55-60 dg, primordial lymph 
nodes form in the prescapular region with the development of the lymphoid, erythroid, 
myeloid and megakaryocytic series. The lymph nodes become integrated into a 
lymphatic system at approximately 65 dg.
99
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 Fetal cells have phagocytic activity by 17 dg. If bacteria or india ink are 
inoculated intravenously in fetuses at 20 dg, phagocytized material can be observed in 
cells in hepatic sinusoids, in blood monocytes, and in the endothelium of multiple 
organs. This phagocytosis presumably occurs in the absence of immunoglobulin 
opsonins. The development of complement is detected at 120 dg.
99
 
 The placenta in ruminants is syndesmochorial; thus, the uterine tissues and 
chorionic epithelium form a barrier that prevents transplacental passage of 
immunoglobulins from the ewe to the fetus.
145
 Inducing placental vasculitis has been 
shown to allow antibodies to move from the dam to the fetus and placental fluids, but 
antibodies are unlikely to be identified in fetal serum.
112
 Antibodies against 
bacteriophages can be identified as early as 35-40 dg. It is believed that there is a 
hierarchy of antibody response depending on the nature of the inoculated antigen.
131,132
 
However, some studies, have shown that antibody response is usually inconsistent and 
has only been measured as present (quantitative), but without evidence of specifity 
(qualitative). Even though ovine fetuses are able to respond to antigens between 60 and 
75 dg, no production of effective IgG antibodies usually occurs after the fetus is older 
than 87 dg.  Fetuses are incapable of producing antibodies against Salmonella organisms 
until birth, even though they are able to respond to the infection by producing what were 
interpreted as nonspecific immunoglobulins.
46,47
 In experiments, when antigens are 
inoculated prior to the development of an adaptive immune response, immune tolerance 
usually is not observed in challenged fetuses.
47
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 Specific viral neutralizing antibodies were found at 75 dg in fetuses directly 
inoculated after 50 days, and antibody appearance correlated with the elimination of 
viable virus from infected tissues.
94
 In another study, IgG and IgM antibodies against 
Akabane virus only were identified after 76 dg.
106
 A third study evaluating the immune 
response of ovine fetuses infected with Akabane virus demonstrated cells with IgG and 
IgM in the spleen of fetuses at 59-60 dg; however, no significant neutralizing antibody 
titer developed at that point.
102
 
 Cell-mediated immune response with allograft rejection has been described as 
early as 70 dg, and if ovine fetuses are given an allograft between 55-65 dg, the grafts 
were accepted, and no allograft immune response developed.
99
 Development of a 
cellular infiltrate/proliferation in the brain of ovine fetuses infected with Akabane virus 
starting at 50 dg, was interpreted as a non protective immunity, although identity of the 
cells was not determined.  However, increased cellular infiltration/proliferation failed to 
occur in fetuses exposed to Akabane virus before 40 dg.
94
  
 
Innate immune response and bunyaviruses 
 
Innate immunity creates epithelial barriers associated with innate immune 
response that block entry of microorganisms by cells, such as phagocytic cells 
(neutrophils and macrophages), dendritic cells and natural killer cells, and proteins of the 
complement system. The most important cellular reactions in innate immune response 
include inflammation, characterized by phagocytosis of pathogens by macrophages and 
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neutrophils, and an antiviral defense mediated by natural killer cells and dendritic cells. 
These cells recognize pathogen associated molecular patterns (PAMPS) on foreign 
pathogens which results in activation of transcription factors and produce type I 
interferon that stimulates production of antimicrobial cytokines and proteins by the 
leukocytes. Examples of PAMPS include toll like receptors (TLR) 7 and TLR8, which 
recognize single stranded RNA.
82
 
The genes within the interferon pathway promote cell survival and inhibition of 
virus replication during a viral infection.  Some interferon stimulated genes (ISG), such 
as ISG15, myxovirus resistance factor (Mx) and 2’5’-oligoadenylate synthetase (OAS) 
are shown to be produced in response to viral infection.
27,130
 Using real-time quantitative 
PCR, upregulation of ISG and continuous stimulation of the innate antiviral response has 
been demonstrated in blood and tissues of fetuses and steers infected with bovine viral 
diarrhea virus (BVDV).
130
 
 The Mx protein is an interferon-stimulated GTPase. This GTPase is located in 
intracellular membranes and is involved in intracellular trafficking, membrane 
remodeling and fusion processes. Mx proteins can be upregulated by type I and type II 
interferons and are capable of restricting growth of several viruses, including influenza 
virus, measles virus and bunyaviruses within the bunyavirus, phlebovirus and hantavirus 
genuses.
50,58-61,66,76,77,139
 In most viral infections, the Mx protein acts by interfering with 
transport of viral components to the target compartments in infected cells. In a model 
proposed by Haller and Kochs (2002),
59
 MxA forms large, membrane-associated self-
assemblies that store monomers of this protein. With infection, monomers bind to viral 
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target structures, forming new assemblies involving viral intermediates and leading to 
mislocalization of viral components and consequent viral inhibition.
59
 The human MxA 
has been shown to inhibit replication of La Crosse virus by binding to the viral 
nucleocapsid protein and forming large viral copolymers that accumulate in the 
perinuclear region.
76
 In humans, two interferon regulated Mx genes have been identified: 
MxA, that has antiviral activity and MxB, that has no antiviral activity. Previous studies 
have demonstrated antiviral activity of bovine Mx2 in cattle infected with BVDV.
130
 
Interferon tau is a type I interferon that is expressed early in pregnancy during 
development of the ruminant conceptus, and unlike most interferons, is not considered to 
be inducible by viral infection. Expression of interferon tau in the ovine conceptus 
occurs only between 11 to 18 dg and is essential for recognition of pregnancy.
9,10
  
  
Significance of pathogen in human medicine 
 
Two cases of encephalitis caused by CVV have been described in humans in the 
United States.
25,128
 One patient developed severe meningoencephalitis, and died after 4 
months.
128
 The other infected patient developed a mild encephalitis and had a full 
recovery within a few weeks after infection.
25
  
In one serologic study, Bunyawera virus antibodies were associated with 
congenital defects in humans. A significant correlation was shown between 
macrocephalic or microcephalic babies born to women that had antibodies for CVV 
and/or Tensaw virus; however, in this report, the data was not shown, and it is not clear 
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that cross neutralization tests were done to confirm the specificity of the antibodies 
detected and that cross reaction between CVV and Tensaw viruses did not occur.
23
 
Another study failed to identify any significant correlation between seropositivity for 
CVV and women that gave birth to anencephalic babies in Texas.
41
 No other 
bunyaviruses in the Bunyaviridae family have been associated with congenital 
malformations in humans.  Further studies should validate if CVV may be associated 
with specific human congenital malformations. 
Some causes of human arthrogryposis include: mutagenic agents, chromosomal 
abnormalities, toxic chemicals or drugs, hyperthermia, neuromuscular blocking agents 
and mechanical immobilization.
55,141
 Despite significant differences between the 
placentation in humans and that in ruminants, CVV-induced arthrogryposis in ovine 
fetuses could serve as a model to study the development of arthrogryposis in human 
patients. 
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CHAPTER II 
CACHE VALLEY VIRUS INFECTION OF THE OVINE FETUS: TARGET 
CELLS AND INFECTION SEQUENCE 
 
Introduction 
 
 Cache Valley Virus (CVV) is a mosquito-borne Bunyavirus in the 
Orthobunyavirus genus of the Bunyamwera group endemic in the United States that 
causes abortion, fetal death and malformations in small ruminants.
29-31,39,43,44
 The 
Orthobunyavirus genus also includes Akabane virus and Aino virus that are associated 
with abortions and fetal malformations in calves and lambs.
11,126,127
 CVV also infects a 
variety of animal species including horses,
24,79,96
 deer,
16,103
 goats, pig, and caribou.
34
 In 
humans, it can cause encephalitis and meningitis.
25,128
 Outbreaks of CVV with dramatic 
fetal lamb losses have been reported.
29-31,39,44
 
 Experimental ovine fetal infections with CVV and Akabane virus occur during a 
narrow window of susceptibility before development of ovine fetal immunocompetency, 
which occurs at approximately 70-75 dg,
94,113
 with the severity of the fetal lesions 
depending on the fetal age when ovine fetuses are infected. Akabane virus causes severe 
necrosis of fetal brain, skeletal muscle and placenta.
26,81,107 
Fetal malformations are 
unlikely to occur after 40 dg,
107
 and if the fetus survives the infection, lambs are born 
with malformations of central nervous system (CNS) and musculoskeletal (MSK) 
malformations.
26,81,107
 Similarly with CVV, the ovine fetus is susceptible if inoculated 
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before 48 dg, and CVV infection can result in fetal death, stillbirths and congenital 
malformations such as hydrocephalus, hydranencephaly, microencephaly, porencephaly, 
torticollis, scoliosis, and arthrogryposis.
29,30,34,39,44
 Experimentally, embryonic mortality 
and mummification occur if the virus is inoculated before 28 dg, and if the virus is 
inoculated after 48 dg, no malformations have been observed.
30,39
 
 Although previous studies have reproduced CVV-induced malformations in 
ovine fetuses;
30,39
 those studies did not characterize the early histologic lesions and did 
not identify the cells targeted by the virus during early infection. The objective of this 
study was to determine the early lesions and infection sequence of cells infected by CVV 
in the ovine fetus in order to correlate the early lesions with the CNS and 
musculoskeletal malformations seen in spontaneously affected lambs. 
 
Materials and methods 
 
Experimental animals and viral inoculation 
 All procedures in this study were conducted using protocols approved by the 
University Biosafety and Animal Use Committees. Fifteen, seronegative Rambouillet 
ewes were synchronized and bred naturally as previously described.
30
 Pregnancies were 
confirmed ultrasonically by 33 dg. On day 35, the pregnant ewes were transferred to a 
BSL2 confinement building, and the amniotic cavity of each fetus was inoculated with a 
1ml inoculum containing 10
5
 50% tissue culture-infective doses (TCID50) of CVV that 
had been isolated from the allantoic membrane of an experimentally infected animal
30
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(infected group) or 1ml of minimum essential medium (MEM) (mock-infected/control 
group), as previously described.
29,30,43
 Using standard virologic techniques, CVV was 
cultured in Vero cells for preparation of the virus inoculum.
89
 The virus-infected and 
mock-infected ewes were housed in separate, confinement buildings. Ewes were 
monitored three times per day for clinical disease, and heparinized blood samples were 
drawn from ewes every 12 hours after infection for the first 4 days and immediately 
frozen at -80°C for virus isolation. Serum samples were collected from the ewes at day 0 
(pre-infection) and on the day of the necropsy for CVV-serum neutralization testing. 
 
Necropsy, sample collection, tissue preparation and light microscopic tissue 
examination 
 At 7, 10, 14, 21, 28 days post infection (dpi), three ewes (one mock-infected and 
two virus-infected) were humanely euthanized with an overdose of pentobarbital. 
Macroscopic lesions were noted, and fetal tissues, amniotic and allantoic fluids and 
placenta were harvested for testing. One set of fresh samples of brain, spinal cord, 
skeletal muscle, cotyledons, amniotic and allantoic fluids and membranes were frozen at 
-80ºC for viral isolation, and a separate set of fresh tissues were placed in an RNA 
stabilization solution (RNA later, Ambion Life technologies, Calsbard, CA) for PCR 
assays. Fetal tissues and fetal membranes were fixed overnight in 4% paraformaldehyde 
and in Davidson’s AFA (acetic acid, formalin, alcohol) fixative to compare each 
fixative’s performance in immunohistochemistry (IHC) and in situ hybridization (ISH) 
techniques. Tissues were paraffin-embedded and sectioned at 5µm for routine light 
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microscopy using hematoxylin and eosin staining (H&E), IHC, and ISH. Sections 
stained with H&E were evaluated for histologic changes. The distribution of the changes 
observed in the brain was based on previously described ovine fetal brain anatomy.
8
 
 
Development of polyclonal antibody and immunohistochemical analysis for CVV 
 Purified viral proteins prepared from Vero cell culture
118
 were submitted to the 
Proteintech Group, Inc (Chicago, IL) for development of a purified, rabbit polyclonal 
antibody against CVV. Briefly, after development of cytopathic effect, the flasks were 
frozen and thawed 3 times, followed by sonication at 42 watts for 5 min to enhance 
release of cytoplasmic viral particles. The viral solution was clarified by centrifugation 
at 1500 x g for 15 min. The virus was pelleted at 64000 x g for 1 hour in a 20% sucrose 
cushion (Beckman SW27).  The formed pellet was resuspended in Tris-HCl and NaCl 
buffer and added to a continuous 20% to 60% sucrose gradient at 94000 x g for 3 hours. 
All formed fractions were collected and concentrated at 80000 x g on a 10% sucrose 
cushion. All purification steps were conducted at 4ºC. Viral protein content was 
determined by the bisinchinic acid (BCA) protein assay, and the proteins fractionated on 
a polyacrylamide gel in the presence of 0.1% sodium dodecyl sulfate (SDS), according 
to the manufacturer’s recommendations (Thermo Scientific, Rockford, IL). To establish 
sensitivity of the CVV antibody and its approximate working range, a western blot using 
the CVV antibody at a concentration of 100µg/ml on cell lysates of CVV-infected cells, 
was done according to the manufacturer’s recommendations (R&D systems, 
Minneapolis, MN). The purified antibody was used for immunohistochemical evaluation 
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of CVV antigen on deparaffinized sections mounted on positively-charged, silanized 
slides using an automated staining system for immunohistochemistry (DakoCytomation 
Autostainer®, Dako, Carpinteria, CA). Briefly, endogenous enzyme was blocked with 
hydrogen peroxide. Samples were pre-treated with unconjugated avidin and biotin. 
Nonspecific epitopes were blocked with Background Sniper (Biocare Medical, Concord, 
CA). Slides were incubated for 30 min with the CVV polyclonal antibody (1:300), 
followed by incubation for 20 min with the secondary antibody (MACH 2, Biocare 
Medical). Sections were stained with 3.3-diaminobenzidine tetrachloride (DAB, Dako) 
and counterstained with hematoxylin.  
 Tissues were evaluated to determine percentage of infected cells in each 
examined organ and graded as follows: less than 3% of cells positive (+); between 3-
15% of cells positive (++); more than 15% of cells positive (+++). To evaluate cross 
reaction between the anti-CVV antibody and other bunyaviruses, IHC testing also was 
done on deparaffinized sections of stored, formalin fixed tissue blocks known to contain 
La Crosse, Main Drain or San Angelo virus from a previous study.
27
. Similarly, 
additional antigen testing was conducted on blocks from calves infected with Akabane, 
and Rift Valley Fever virus kindly provided by Dr. Makoto Yamakawa (National 
Institute of Animal Health, Japan) and Dr. Sophette Gers (Western Cape Department of 
Agriculture, South Africa), respectively. 
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In situ hybridization for CVV 
 A CVV-specific, digoxigenin (DIG)-labeled, single-stranded cDNA probe was 
generated as previously described.
74,83,117
 Briefly, RNA was extracted and purified from 
CVV-infected cell culture fluid using a RNeasy mini kit (Qiagen, Valencia, CA). A 
unique, 530 bp segment from a conserved region of the CVV-M gene glycoprotein 1 
(GenBank AF082576.1) was amplified by reverse transcriptase polymerase chain 
reaction (RT-PCR) using CVV specific primers (F: AGC CTA GATTGT ATA GAC 
TGT GGA CCA, R: TTG GAT CAA TTG ATA AAA TAA GGA TTC). To generate a 
primarily single-stranded, labeled product, a second PCR reaction was conducted on the 
resulting amplicon using only the reverse primer in combination with a DIG DNA 
labeling mix (Roche Diagnostics, Manheim, Germany) according to the manufacturer’s 
instructions. 
 The ISH assay was conducted on deparaffinized tissue sections mounted on 
positive-charged, silanized slides (ProbeOn Plus; Fisher Scientific, Pittsburg, PA) as 
previously described.
146
 Slides were initially inserted in a slide holder before being 
exposed to a series of solutions utilizing the capillary gap refill technology of the manual 
MicroProbe system (Fisher Scientific) with minor modifications to the described 
protocol. Briefly, following serial hydration steps, the sections were digested with 
Proteinase K (100 µg/ml in phosphate-buffered saline) for 8 min at 37°C, followed by 
post-fixation in 0.4% paraformaldehyde for 10 min at 4°C. The hybridization step was 
performed using 50ng of the CVV-specific, DIG-labeled probe in the hybridization 
cocktail solution (Fisher Scientific, Pittsburg, PA) with an initial 10min incubation at 
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100°C followed by a 2 hour incubation at 42°C. Unbound probe was removed by 
decreasing salt washes (2X to 0.2X standard saline citrate buffer). To detect bound, 
DIG-labeled probe, slides were incubated for 1 hour at 37°C in an alkaline phosphatase-
labeled, anti-DIG antibody solution (Roche Diagnostics) followed by a 30 min 
incubation in a development solution containing the chromagen substrate, nitro-blue 
tetrazolium/5-bromo-4-chloro-3'-indolyphosphate (NBP/BCIP), Lastly, slides were 
dehydrated and counterstained with Bismarck Brown prior to microscopic examination. 
Evaluation of the distribution of the signal in infected organs was performed as 
described for the IHC. In order to evaluate the specificity of our CVV DIG-labeled 
probe, ISH was also performed on deparaffinized tissue sections from animals infected 
with the non-CVV bunyaviruses described above. 
  
Virus isolation 
 Viral isolation from blood and tissues was performed as described previously.
30
 
Inocula included: 1:10 MEM suspensions of either fresh fetal tissues, membranes, 
cotyledons, ewe blood, amniotic or allantoic fluids. The inocula were layered onto 
drained monolayers of Vero cells, incubated for 1 hour at 37°C, and subsequently 
flooded with MEM containing 10% FBS and incubated at 37°C in 5% CO2 for 5 days 
with daily evaluation for cytopathic effect.  
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Serum neutralization   
Ewe serum samples were tested for CVV neutralizing antibodies in triplicates 
using a microtiter, serum neutralization test in 96-well plates as previously described.
30
 
Serum samples were inactivated at 56°C for 30 min and diluted 1:4, 1:8, 1:16, 1:32, 
1:64, 1:128 and 1:256 with MEM. Prior to inoculation, the diluted sera were incubated at 
37°C for 60 min with an equal volume of 100 TCID50/ml of CVV. After incubation, 
Vero cell suspensions diluted in MEM were added to virus-antibody mixtures, and the 
plates were incubated at 37°C in 5% CO2 for 5 days. Monolayers were evaluated daily 
for cytopathic effect, and titers were calculated according to the Spearman Karber 
method.
75,138
 Titers above 1:4 were considered positive.    
 
Results 
 
Gross findings   
Three fetuses were collected from CVV-infected ewes at 7 and 10 dpi and four 
fetuses were collected at 14, 21 and 28 dpi (Table 1). Of the harvested fetuses at 7 dpi, 
one recovered fetus was grossly normal and two fetuses were diffusely dark red with 
pale red amniotic fluid (non-viable). Two, grossly normal fetuses and one non-viable 
fetus were recovered at 10 dpi. At 14 dpi, one recovered fetus was dead in early stages of 
mummification (not included in Table 1), and three fetuses were viable, but one had the 
amnion closely apposed (oligohydramnios) and compressing and bending the body. All 
four fetuses at 21 dpi were viable. One of these fetuses had marked oligohydramnios, 
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torticollis, arthrogryposis and scoliosis (Fig. 1.B), and another fetus had mild kyphosis. 
Three viable fetuses and one mummified fetus (not included in Table 1) were recovered 
at 28 dpi. One of these fetuses had moderate oligohydramnios with torticollis and 
hypercontracted flexed frontlimbs (arthrogryposis). 
 
Table 1. Gross findings observed in fetuses infected with CVV 
Ovine Fetus # dpi/dg Gross Findings 
   
1 7/42 NF 
2 7/42 Dark red fetus and fluids (dying) 
3 7/42 Dark red fetus and fluids (dying) 
4 10/45 NF 
5 10/45 NF 
6 10/45 Dark red fetus and fluids (dead) 
7 14/49 NF 
8 14/49 Oligohydramnios, kyphosis 
9 14/49 NF 
10 21/56 NF 
11 21/56 Mild concave spinal flexion 
12 21/56 Oligohydramnios, torticollis, arthrogryposis and kyphosis 
13 21/56 NF 
14 28/63 Oligohydramnios, arthrogryposis, torticollis 
15 28/63 NF 
16 28/63 NF 
______________ 
NF: No gross findings.
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Figure 1. Gross findings in control and infected ovine fetuses. A. Control fetus at 56 dg. 
The fetus is floating freely within the amniotic cavity. B. Ovine fetus infected with 
CVV, 21 dpi (56 dg). Severe oligohydramnios results in fetal membranes apposed to the 
body of the fetus. The fetus has scoliosis at the level of cervical and thoracic vertebrae. 
Inset: Severe arthrogryposis is manifested by hypercontraction of the limbs. 
 
A 
 B 
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Histologic findings  
Most histologic lesions in infected fetuses were limited to the CNS and 
musculoskeletal system (MSS). Multifocal, severe areas of necrotic debris without 
inflammation were observed in the brain (BRA), spinal cord (SPC) and skeletal muscle 
(SKM) at 7 dpi. The areas of severe necrosis affected primarily the matrix zone and 
mantle layers of the telencephalon with moderate scattered necrotic areas affecting the 
brainstem and gray matter of the spinal cord, especially in the dorsal horns. No vessel 
lesions or thromboses were noted. The appendicular and dorsal SKM had multifocal, 
moderate to mild necrotic areas. 
 At 10 dpi, areas of necrosis were observed affecting the matrix and intermediate 
zones of the telencephalon and brain stem. Moderate necrosis was seen in the dorsal 
horns of the SPC. Necrosis similar to that observed at 7 dpi was seen in the SKM. In 
addition, SKM had multifocal, mild clusters of infiltrates of granulocytes within and 
among the SKM fibers along with multifocal, mild hemorrhage. Perivascular 
accumulations of cellular debris were observed in the fetal membranes of the non-viable 
fetuses.  
At 14 dpi, multifocal, moderate areas of necrosis were in all layers of the 
ventricular walls of the telencephalic wall and in the brain stem resulting in 
hydrocephalus ex vacuo (Fig. 2.B1). The necrosis noted in the SPC was more extensive 
and severe than observed at 7 and 10 dpi (Fig. 3.B1). An infiltrate of mononuclear cells 
was observed in the meninges of the BRA and SPC. No significant necrosis was 
observed in the SKM; however, small aggregates of mononuclear cells and granulocytes 
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were within the SKM (Fig. 4.B1), focally in the tongue and in the smooth muscle of the 
intestine. Marked perivascular accumulation of necrotic cellular debris was observed in 
the amniotic membrane of the mummified fetus. 
 At 21 dpi, severe necrosis, loss of neuropil, meningeal inflammatory infiltration 
(meningitis) and hydrocephalus ex vaccuo were observed in the BRA. The SPC of three 
infected fetuses had marked parenchymal loss and micromyelia. BRA and SPC had 
multifocal areas of mineralization. Focal mononuclear cell myositis was also observed 
along with reduction in the thoracic and lumbar dorsal muscle mass in two fetuses. 
Findings at 28 dpi were similar to those observed in the SPC, BRA and SKM of fetuses 
at 21 dpi, with less necrotic tissue and severe hydrocephalus (Fig. 2.B2) and 
micromyelia (Fig. 3.B2). Moderate reduction in the dorsal SKM mass was observed in 
one of the fetuses at 28 dpi (Fig. 4.B2). Additionally, one fetus had mild, focal necrosis 
in the tubular epithelial cells of the kidneys. Hypercontraction of myotubules and mild 
mononuclear perivascular and interstitial infiltrates were observed in the SKM of both 
control and infected fetuses at 21 and 28 dpi; however, most infected fetuses had slightly 
greater numbers of mononuclear cells in meninges.  
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Figure 2. Histology of telencephalic wall of control (A) and CVV-infected fetuses (B). 
Regions of the telenchalic wall are marked as: Ma, marginal layer; Pl, primordial layer; 
Iz, intermediate zone; Mx, matrix layer; Mt, mantle zone, which is the most external 
layer of the matrix layer. Multifocal areas of necrosis characterized by accumulation of 
necrotic and karyorrhectic debris are seen at 14 dpi (B1). The telencephalic wall was 
markedly thinner due to cellular loss at 28dpi (B2). H&E; 100X mag; inset 400X mag. 
B2 
A2 
14dpi 28dpi 
In
fe
ct
ed
  
 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
C
o
n
tr
o
l 
A1 
B1 
  
27 
2
7
 
 
Figure 3. Histology of spinal cord at the thoracic level of control (A) and CVV-infected 
fetuses (B). Multifocal areas of necrosis with accumulation of necrotic and karyorrhectic 
debris are seen in the gray matter (B1). Progressive cellular and parenchyma loss with 
micromyelia is noted at 28 dpi (B2). H&E; 100X mag. 
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Figure 4. Histology of skeletal muscle of control (A) and infected fetus with 
arthrogryposis (B). Scattered inflammatory infiltrates composed of granulocytes and 
mild hemorrhage are within skeletal muscle fibers of a 14 dpi fetus (B1). At 28 dpi (B2) 
loss of skeletal muscle fibers were evident on the dorsal skeletal muscle around 
vertebrae. H&E; 400X mag. 
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Distribution of IHC viral antigenic signal in fetuses infected with CVV  
The IHC CVV antigen signal in infected fetuses is shown in Table 2 and results 
were identical for tissues fixed in both fixatives. The tissues with abundant viral signal 
included the BRA, SPC and SKM with the signal primarily associated with necrotic foci. 
Within the BRA, the distribution of intense viral signal was diffuse within the 
telencephalic walls at 7 and 10 dpi, whereas it was mainly within the matrix zone at 14 
dpi (Fig. 5.A2), and the mantle layer and primordial layers at 21 dpi. Only scattered foci 
had positive cells throughout the telencephalic walls at 21 dpi. The SPC had intense and 
diffuse viral signal distribution throughout all levels of the spinal cord at 7 and 10 dpi, 
but primarily within the dorsal aspect after 14 dpi. Viral signal was also identified in 
many myotubules and myofibers in the developing SKM around the vertebrae and ribs 
(Fig. 5.A3) with slightly fewer cells being positive within the SKM of the front and hind 
limbs, especially after 21 and 28 dpi. Virus-positive cells were cleared from SKM earlier 
than from the CNS. Scattered positive cells were observed in the neurons of the retina 
and ganglia, cardiomyocytes, and renal tubular and glomerular epithelial cells. Rare, 
positive cells were seen in the media of the aorta, as well as in the lymph nodes and 
spleen. Scattered mesenchymal cells in the fetal membranes were positive and the 
amniotic membranes were more intensely affected than the allantoic membranes. The  
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amniotic epithelium appeared to be rarely infected. No viral protein signal was observed 
in the cotyledons. A progressive decrease in viral antigen was observed in most affected 
tissues as the infection progressed, with rare positive cells noted in tissues at 28 dpi. IHC 
viral antigen signal was not observed in tissues collected from control animals and the 
antibody did not cross react with antigens in tissues of animals infected with other 
bunyaviruses.  
 
Distribution of ISH CVV viral signal in fetuses infected with CVV 
The distribution of the ISH CVV viral signal is shown in Table 2, and results 
were identical for tissues fixed in both fixatives. Similar to the results observed with the 
IHC, the tissues with most abundant viral signal were BRA (Fig. 5.B2), SPC and SKM 
(Fig. 5.B3). The distribution and quantity of signal in other tissues were similar to those 
observed with IHC, although the viral signal appeared reduced in comparison to that 
observed with IHC.  Tissues collected in early infection had more intense signal when 
compared to those of later infection. Viral signal was not identified in the fetal 
membranes using this ISH protocol. ISH signal was not observed in tissues collected 
from control animals or from animals infected with other bunyaviruses.  
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Table 2. Detection of CVV in tissues of infected fetuses at different days of gestation  
Tissues Brain Spinal Cord Sk muscle Ganglion Heart Kidney Eye Allantois Amnion 
Al 
Fluid 
Am 
Fluid 
Dpi Methods 
Fet# 
IHC ISH VI IHC ISH VI IHC ISH VI IHC ISH IHC ISH IHC ISH IHC ISH IHC VI IHC VI VI VI 
7 
1 +++ +++ +1 +++ +++ 
 
+++ +++ +1 +++ +++ + - ++ + 
  
++ +1 +++ +1 + +1 
2 +++ +++ 
 
+++ +++ 
 
+++ +++ 
 
+++ +++ + + + + + + ++ +1 ++ +1 +1 +1 
3 +++ +++ 
 
+++ +++ 
 
+++ +++ + ++ ++ - - ++ ++ - - + + +++ + +1 + 
10 
4 +++ +++ +1 +++ +++ +1 +++ +++ +1 ++ ++ ++ + - - ++ + - + +++ + +1 +1 
5 +++ +++ +1 +++ +++ +1 +++ ++ +1 + + ++ 
 
+ - ++ + 
 
- 
 
+1 +1 +1 
6 
  
+ 
     
+ 
         
- 
 
+ + + 
14 
7 +++ +++ + +++ +++ +1 ++ + +1 + - + - ++ ++ ++ + - +1 + +1 + +1 
8 +++ +++ +1 +++ +++ +1 +++ + +1 ++ + ++ + ++ ++ ++ + + - + +1 + + 
9 +++ +++ +1 +++ +++ +1 +++ +++ - + + + - + + ++ ++ + +1 ++ +1 +1 +1 
21 
10 +++ +++ + ++ ++ + + - - + - - - + + ++ + + - + + + + 
11 ++ ++ +1 ++ + +1 + - + + - + - + + + 
 
+ + + +  + 
12 +++ +++ 
 
++ + +1 ++ ++ +1 ++ + + - ++ + ++ + - + + + + +1 
13 ++ ++ +1 ++ + +1 ++ + +1 + + + - + + + - 
 
+ ++ 
 
+ - 
28 
14 ++ ++ +1 + + +1 + - + - - + - + - + + - - + + + - 
15 ++ ++ +1 + + - + + - + - + - + - + + - + - + + + 
16 + + +1 - + - - - + - - - - - - - 
 
- + ++ + +1 + 
Dpi: days post infection; IHC: immunohistochemistry; ISH: in situ hybridization: VI: Viral isolation; 
1
: Virus was isolated at 
1
st
 passage. Blank spaces indicate samples that were not examined. 
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Figure 5. Immunohistochemistry and in situ hybridization in brain and skeletal muscle. 
A rabbit polyclonal antibody against CVV and stained with DAB chromagen (brown) 
was used to detect CVV protein in the brain of a control (A1) and an infected fetus (A2) 
and in the skeletal muscle of an infected fetus at 14 dpi (A3). In situ hybridization using 
a digoxigenin labeled DNA probe complementary to a conserved region of the CVV M 
gene glycoprotein 1 and labeled with BCIP/NBT (blue) was performed in brain from 
control (B1) and infected fetuses (B2) and skeletal muscle from an infected fetus at 14 
dpi (B3). No viral signal was detected in the brain of control fetuses (A1, B1) Numerous 
cells in the brain (A2, B2) and skeletal muscle (A3, B3) are positive for CVV viral 
protein (A2, A3) and for the CVV M glycoprotein 1 (B2,B3). 400X mag. 
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Viral isolation 
The virus isolation results are summarized in Table 2. Virus was isolated from 
most examined tissues, except for the cotyledons, where virus was isolated only from 
one 7-day infected fetus on 3
rd
 passage. Virus was isolated on 1
st
 passage mainly from 
BRA and SPC, as well as from amniotic fluids and membranes. No virus was isolated 
from blood collected from infected ewes. No virus was isolated in any tissue collected 
from control animals. 
 
Serum neutralization 
 All infected ewes seroconverted to CVV, except for one ewe euthanized at 7 dpi. 
On the day of euthanasia, the serum neutralizing antibody titer for infected ewes were: 
1:16 at 7 dpi, 1:8 and 1:32 at 10dpi, 1:16 and 1:32 at 14 dpi, 1:32 and 1:64 at 21 dpi, and 
1:64 and 1:128 at 28 dpi. No control animals seroconverted for CVV.   
 
Discussion 
 
This study focused on CVV-induced, gross and histologic lesions and the 
distribution of the virus during infection of ovine fetuses from 35 to 63 dg (28 dpi). The 
brain and skeletal muscle lesions noted in this experimental infection have a distribution 
and degree of involvement that correlates to those observed in spontaneous natural 
infections.
29,31,39
 Although previous experimental infection studies using the intrauterine 
route of inoculation with CVV have reproduced the syndrome seen in ovine fetuses in 
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field outbreaks.
30,39,43,67
 the sequence of changes in the infected cell populations and their 
distribution in tissues has not been done. Success of experimental infection of ovine 
fetuses using the intravenous inoculation of pregnant ewes with CVV is unpredictable 
even with high doses of low passage isolates.
42
 Low transplacental fetal infection rates 
have occurred in experiments with Akabane virus as well.
81,110
 The reason for the low 
success of some arbovirus transplacental infection by intravenous infection remains a 
fertile area of research and is speculated to involve ability of  effector molecules in 
vector saliva injected with the virus into the mammalian host to amplify the primary 
viremia.
42
 In order to avoid failure of transplacental infection in this study and reduce the 
number of animals, the intrauterine route of inoculation was used.  
 The data supports the hypothesis that the fetal central nervous system and 
skeletal muscle are targeted in CVV infection. Severe necrosis in stained sections of 
brain, spinal cord and skeletal muscle of infected fetuses was observed coincident with 
the presence of infected cells as seen with both IHC and ISH. Such lesions reasonably 
would result in the hydrocephalus, porencephaly, micromyelia and body malformations 
described in lambs associated with CVV outbreaks.  Viral signal was also observed in 
other cells of the peripheral nervous system, including the ocular retinal cells and in 
ganglion cells in the dorsal root ganglia, but the result of these lesions have not been 
investigated in spontaneous cases of CVV-malformed lambs. In spontaneous and 
experimental cases of CVV
2
 and Akabane virus,
26,80,81,107
 lesions in the spinal cord affect 
both the dorsal and ventral horns, with slightly more severe lesions involving the ventral 
motor neurons. In this study, most fetuses at 7-14 dpi had more severe lesions and 
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intense viral signal in the dorsal horns, even though, in the fetuses at 21 and 28 dpi, the 
loss of parenchyma affected both the dorsal and ventral horns and caused severe 
micromyelia. Both direct infection of the SKM and the indirect changes associated by 
possible denervation atrophy probably contribute to the development of musculoskeletal 
malformations. In addition to the CVV tropism for the SKM, the virus also appears to 
target other myocytes in the fetuses. Although necrosis was not seen on light 
microscopy, viral signal was seen in the cardiac muscle and smooth muscle of the 
gastrointestinal tract of some fetuses.  
 Fetal membranes and placental fluids have been shown to contain virus in early 
infection.
29,34,39,43
 In this study, CVV was isolated from and it persisted in the fetal 
membranes and fluids throughout infection. Using IHC, virus was seen to infect cells of 
the amniotic and allantoic mesenchyme, but more mesenchymal cells and only rare 
epithelial lining cells of the amniotic membrane were infected. With the progression of 
the infection, fewer cells were seen to be infected, but virus levels still persisted in fetal 
membranes and fluids. Although functional testing of the membranes was not done, it 
may be speculated that viral infection disrupts the intramembranous movement of fluid 
in the amnion that contributes to the oligohydramnios. In ovine fetuses, the 
intramembranous pathway is considered a major route of absorption of water from the 
amniotic cavity.
48,52-54
 The ISH technique failed to identify viral signal in fetal 
membranes. This lack of signal is presumed to be related to degradation of viral RNA 
from these thin specimens, most likely during sample storage in the fixative solution 
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prior to testing. Use of shorter fixation times for this assay is recommended in future 
studies. 
 In the first experimental infections with CVV, virus was routinely isolated from 
cotyledons,
30,31
 but in the present study, low viral levels were detected in the fetal 
cotyledon in only one infected fetus. Examination of infected tissues showed limited 
involvement of trophoblasts. We speculate that the previous reported success in CVV 
isolation from this tissue could have resulted from contamination due to the proximity of 
high titered fetal membranes and fluids. The limited involvement of trophoblasts in the 
experimental infection presumably reflects the artificial intrauterine route of fetal 
infection. Intravenous infection with Akabane virus has been shown to cause more 
necrosis with more viral antigen detected in the trophoblasts and placentomes.
110
  
One cause of congenital limb and axial skeletal malformations is the decreased 
fetal movement (fetal akinesia)
5,55,56,100,120,129,133
 associated with oligohydramnios. Spinal 
flexion and the resulting increased pulmonary and abdominal compression along with 
diaphragmatic displacement have also been described in ovine fetuses with 
experimentally induced oligohydramnios produced by drainage of amniotic and allantoic 
fluids in late gestation.
63
 Based on experimental studies with ovine fetal fluid drainage 
and the demonstration of CVV-induced oligohydramnios,
39,41
 fetal akinesia also could 
play a role in the pathogenesis of the musculoskeletal deformities observed in CVV 
infection. Many processes may affect amniotic fluid volume. For example, experiments 
performed in ovine fetuses have also demonstrated that severe placental insufficiency 
resulting in hypoxia and hypercapnia, alters the amniotic fluid composition and can be 
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associated with the development of oligohydramnios.
51
 The association of severe viral 
infection with development of oligohydramnios has only been reported with ovine CVV 
infection. In the present study, three infected fetuses displayed severe oligohydramnios 
with axial and limb deformities relatively early in fetal life. Obviously, the CNS and 
muscle lesions induced by CVV must contribute to these lesions. Abnormalities 
affecting the central and peripheral nervous systems are actually considered to be the 
most common cause of decreased fetal movement in affected fetuses with subsequent 
development of arthrogryposis.
55
 In this study, one infected animal at 21 dpi had 
kyphosis, without oligohydramnios. The combined effect of the CNS and skeletal 
muscle lesions, and oligohydramnios early in fetal development would explain the 
severe axial and limb malformations often seen in lambs born after CVV infection. Even 
though oligohydramnios has not been described in experimental Akabane virus 
infections, lung hypoplasia, a component of the “oligohydramnios tetrad” associated 
with oligohydramnios in human fetuses,
120,141,143
 has been seen in some ovine fetuses 
experimentally infected with Akabane virus.
107
 Considering this finding, 
oligohydramnios may occur with other bunyaviral infections. 
Another mechanism associated with the development of oligohydramnios is renal 
disease. In this study it was seen that CVV-infected scattered cells of the renal tubules 
and glomerulae. The ovine fetal mesonephros is functional and able to produce urine that 
is excreted into the allantoic cavity as early as 30 dg.
35,150,151
 The vast majority of the 
urine produced in early gestation is primarily transferred to the allantoic cavity via the 
urachus.
6,147,151
 The origin and control of amniotic fluid during early gestation of ovine 
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fetuses has not been completely elucidated.  However, since the amniotic fluid during 
early gestation is believed to be primarily an ultrafiltrate of fetal blood plasma, renal 
disease could possibly affect amniotic fluid volume.
28,92
 If one considers the possibility 
that the fetal urine production also contributes to the formation of the amniotic fluid in 
early gestation, even mild infection of the fetal kidney could possibly affect fetal urine 
production and consequentially contribute to oligohydramnios. In any case, renal virus 
load is mild, and necrosis was only observed in one fetus at 28 dpi. 
The IHC and ISH protocols developed to identify CVV in experimentally infected 
tissues from ovine fetal tissues, could be further used for diagnostic purposes to confirm 
or rule out natural cases of CVV on properly collected tissues. Both techniques tested 
specific for CVV, and could be used to differentiate between CVV and Akabane virus 
infection, since no signal was detected in specimens previously confirmed to be positive 
for Akabane virus by IHC. Certainly in areas where other bunyaviruses are active, it 
would be advisable to test the specificity of this antibody to other viruses. In terms of 
sensitivity, the IHC seemed more sensitive than ISH and identified viral protein in some 
infected tissues not identified with ISH. Additionally, IHC frequently detected a higher 
percentage of cells infected with CVV in different tissues. However, some sensitivity in 
identifying virus may be improved by reducing fixation times particularly in fetal 
membranes. Both IHC and ISH represent excellent tools for further investigational 
studies, as well as for diagnostic purposes in the detection of CVV in early abortions. 
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CHAPTER III 
CACHE VALLEY VIRUS CENTRAL NERVOUS SYSTEM TROPISM AND 
TARGET CELLS IN INFECTED FETUSES 
 
Introduction 
 
Cache Valley virus (CVV) was first isolated from a mosquito pool collected in 
1956 in Cache Valley, Utah.
69
 CVV is endemic in the United States,
21,22,95
 and has been 
established as an infectious cause of abortion and fetal malformations in small 
ruminants.
29-31,39,44
 Serologic evidence of human infection with rare reported cases of 
encephalitis and meningitis are also described.
23,25,93,128,142,148
 
CVV is a member of the family Bunyaviridae, Orthobunyavirus genus, 
Bunyamwera group. The viruses within the Orthobunyavirus genus are transmitted by 
mosquitoes, and this genus includes several viruses that infect or cause encephalitis in 
humans, including the members of the California group, such as: California encephalitis 
virus, La Crosse virus, Jamestown Canyon virus, Snowshoe hare virus. A member of the 
Simbu group, Akabane virus, causes abortions and fetal malformations in ruminants, 
similar to those caused by CVV. 
11,126,127
 The forms of diseases in mammalian hosts 
infected with orthobunyaviruses can be simplistically divided into either primary CNS 
infection with encephalitis in mature animals or transplacental fetal infections with 
subsequent fetal malformations. 
109
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In sheep, CVV is responsible for embryonic and fetal death, stillbirths and 
congenital central nervous system (CNS) and musculoskeletal system (MKS) 
malformations.
29,30,34,39,44
 It has been shown that CVV
30,31,39,44
 and Akabane 
virus
26,36,108,110
 infect cells primarily in the brain and spinal cord of sheep; however, no 
studies have determined which cells within the CNS are susceptible to viral infection. 
Nor has any study described changes in the resident cell populations in the CNS beyond 
necrosis. In order to determine specific cell populations within the CNS that are infected 
by CVV, as well as any changes in these cell populations that may occur, we employed 
indirect fluorescent microscopy using a double-labeling technique against CVV and 
different cell types within the CNS. 
 
Materials and methods 
 
The ovine fetal samples used in this study were collected from pregnant ewes 
infected with CVV as described on Chapter II. Briefly, CVV-seronegative ewes at 35 dg 
were inoculated in utero with 1ml of minimum essential medium (MEM) (mock-
infected/control group) or with a 1ml inoculum containing 10
5
 50% tissue culture 
infection doses (TCID50) of a second passage of a CVV isolate from the infected 
allantoic membranes of an experimental study.
30
 Three ewes (one mock-infected and 
two virus-infected) were humanely euthanized at 7, 10, 14, 21, 28 dpi (dpi). Samples 
were harvested and fetal tissues were collected and fixed in 4% paraformaldehyde or in 
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Davidson’s AFA (acetic acid, formalin, alcohol) fixative for routine histologic 
processing paraffin-embedding. 
Paraffinized tissue sections of the brain and spinal cord from control and infected 
fetuses were mounted on positive-charged, silanized slides, deparaffinized and heat 
treated at 120°C for 30 min in sodium citrate buffer (10mM sodium citrate, 0.05% 
Tween 20, pH6.0) for antigen unmasking and retrieval. Sections were further washed 
with phosphate buffered saline (PBS) and blocked with PBS-T (1X PBS, 0.1% Triton X-
100) containing 5% goat serum for 1 hour at room temperature. The slides were 
incubated at 4°C overnight with antibodies against neurons (mouse anti-NeuN, clone 
A60, Millipore, Temecula, CA; diluted 1:80); astrocytes (mouse anti-glial fibrillary 
acidic protein (GFAP), clone GA5, Millipore; diluted 1:300); neural stem cells and 
macroglia (rabbit polyclonal anti-Olig2, Millipore; diluted 1:100); or microglia (rabbit 
polyclonal anti-Iba1, Wako, Chuo-Ku, Osaka, Japan; diluted 1:500). After several 
washes, the secondary antibody conjugated with Alexa Fluor 594 (Invitrogen, Eugene, 
OR; diluted 1:1000) was applied and incubated for 1 hour at 25°C. Following additional 
washes, sections were incubated overnight at 4°C with a second primary antibody, anti-
CVV (diluted 1:300). After several washes, the secondary antibody conjugated with 
Alexa Fluor 488 (Invitrogen; diluted 1:1000) was incubated for 1 hour at 25°C. Finally, 
the nuclei were stained with Hoechst 33258 (Invitrogen) at a ﬁnal concentration of 2 
µg/mL for 1 min, and a solution containing Sudan Black was used to inhibit 
autofluorescence. Sections were mounted and coverslipped with Fluoromount-G 
(Southern Biotech, Birmingham, AL) and kept in the dark at 4°C. The sections labeled 
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with anti-Iba1 (rabbit) were not double-labeled with CVV. In order to do double-labeling 
with CVV and Iba1, additional serial sections were stained with another antibody against 
microglia (a goat polyclonal anti-Iba1, dilution 1:300; Abcam, Cambridge, MA) using a 
modified protocol using PBS-T containing 5% donkey serum to block non-specific 
binding. The first primary antibody used was CVV followed by binding with secondary 
antibody AlexaFluor 488. Sections were blocked again with 5% rabbit serum, and anti-
Iba1 (goat; diluted 1:300) was used as the second primary antibody followed by binding 
with the secondary antibody AlexaFluor 594. In addition, the following antibodies were 
also tested in the brain and spinal cord of control and infected fetal tissues at 63 dg: 
myelin proteolipid protein (PLP) (mouse anti-PLP, clone AA3, gift from Dr. Jianrong 
Li, Texas A&M University; dilution 1:500), Nestin (rat anti-nestin, clone 401, dilution 
1:200; Millipore), neurofilament (mouse anti-phosphorylated neurofilament, clone 
SMI31, dilution 1:200; Covance, Emeryville, CA), myelin associated glycoprotein 
(MAG) (hamster polyclonal ascitic fluid anti-MAG, not diluted; gift from Dr. Jianrong 
Li, Texas A&M University), myelin basic protein (MBP) (rat polyclonal anti-MBP, 
dilution 1:100;Millipore), Olig1 (mouse polyclonal anti-Olig1, dilution 1:100; 
Millipore). Slides were incubated, washed and stained with similar concentrations of 
Alexa Fluor conjugated antibody as above to assay for activity. The primary antibody 
was not used in negative control sections.  
Tissue images were captured with a ﬂuorescence microscope (Olympus IX71) 
equipped with an Olympus DP70 digital camera (Leeds Instruments, Irving, TX, USA). 
To evaluate changes in microglial cell populations and expression of GFAP in infected 
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and non-infected fetuses, images were obtained from ten different fields for each 
antibody and color intensity was measured using ImageJ (National Institute of Health 
(NIH), USA). The background of captured images was equally corrected for each 
antibody using ImageJ. 
The averages of the measurements obtained for each slide were subjected to the 
least square analysis of variance (ANOVA) to determine differences between infected 
and non-infected groups. Differences between groups of different dpi were subjected to 
the one pair students t-test. In order to reduce heterogeneity between samples, the data 
was log-transformed, and p-values below 0.05% were considered statistically significant. 
The data is presented as means with overall standard error. 
 
Results 
 
The NeuN antibody identified the nuclei of developing neurons in the brain and 
gray matter of the spinal cord of control and infected fetuses at different dg. A large 
amount of CVV viral antigen signal was detected around the neuronal nuclei, and this 
was interpreted to be within the cytoplasm of neurons (Fig. 6). In addition, viral signal 
was detected free within the parenchyma and within the cytoplasm of NeuN-negative 
cells. CVV viral signal was distributed diffusely within the telencephalic walls, 
brainstem and spinal cord at 7, 10, 14 and 21 dpi, and only scattered foci had viral 
positive cells in the brain and spinal cord at 28 dpi, as shown in Chapter II.  
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Figure 6. Immunofluorescence for NeuN and CVV in the brain and spinal cord of 
infected fetuses. Sections of CNS labeled with NeuN (a,e), CVV antigen (b,f), double 
labeled with CVV (c,g) and double-labeled merged with Hoechst nuclear staining (d,h). 
Large numbers of NeuN-positive cells in the brain (c,d) and spinal cord (g,h) have 
intracytoplasmic viral signal. Viral signal is shown in the cytoplasm of NeuN-negative 
cells (d,h) (arrows). 
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GFAP was weakly expressed in the fetal brain after 56 dg (21 dpi); whereas, 
GFAP expression was stronger and more consistent in the spinal cord after 49 dg (14 
dpi). In the brain, GFAP expression was mainly seen in periventricular regions. The 
spinal cord had more diffuse and intense GFAP expression. Usually, CVV viral signal 
did not colocalize with astrocytic processes and cytoplasm. No significant difference 
was observed in the expression of GFAP in sections of brain and spinal cord of infected 
versus non-infected fetuses (Fig. 7).  
 
 
Figure 7. ImageJ measured intensity of GFAP in the brain and spinal cord of control and 
CVV-infected fetuses. No significant difference was detected in brain and spinal cord 
labeled with GFAP. p > 0.05  
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Both Iba1 antibodies used in this study detected microglia in the brain and spinal 
cord of control and infected animals. The goat anti-Iba1 was used for double-labeling 
with CVV; whereas, the rabbit anti-Iba1, due to its better cellular definition, was used to 
determine microglial cell numbers in the CNS. No colocalization between CVV and the 
cytoplasm of microglial cells was observed in examined sections from the brain and 
spinal cord of infected or control fetuses. Even though viral signal was not observed in 
microglial cells, a significant increase in the expression of the microglial marker (Iba1) 
was observed in sections of brain (p-value <0.05) and spinal cord (p-value <0.005) in 
infected versus non-infected fetuses, especially around areas with abundant viral signal 
(Figs. 8 and 9). The data was pooled into two groups, infected and control, because no 
significant difference was observed between infected fetuses comparing each dpi, or 
control fetuses comparing each dg. Increased expression of the microglial marker were 
in infected fetuses as early as 42 dg (7 dpi) and even though a significant difference was 
not observed between different days of infection, on average, the highest expression of 
the microglial marker was observed in the brain and spinal cord at 14 dpi in infected 
fetuses followed by a progressive reduction in the expression of the microglial marker in 
the brain at 21 and 28 dpi. A constant reduction of the expression of the microglial 
marker was noted in the spinal cord at 21 and 28 dpi. 
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Figure 8. Immunofluorescence for Iba1 and CVV in the brain. Serial sections from the 
cerebrum of a control (a-d) and an infected (e-h) fetus at 63 dg/28dpi. The control fetus 
has few Iba1-positive cells (a,b), and there is no viral signal (c,d). The infected fetus has 
a marked increase in the number of Iba1-positive cells (microglia) (e,f). The same region 
has strong viral signal (g,h). 
 
 
Figure 9. ImageJ measured intensity of Iba1 in the brain and spinal cord of control and 
CVV-infected fetuses. A significantly greater intensity of Iba1 was in the brain and 
spinal cord of infected versus control fetuses. *p < 0.05, **p < 0.005.  
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Olig2-positive cells were identified multifocally in the brain of control and 
infected animals after 45 dg (10 dpi) and scattered cells were identified in the spinal cord 
after 49 dg (14 dpi). In the brain, these scattered Olig2-positive cells were identified in 
areas that corresponded to regions with large numbers of NeuN-positive cells. Scattered 
viral signal was observed around Olig2-positive cells in the brain of infected animals at 
14, 21 or 28 dpi, and only rare Olig2-positive cells in the spinal cord had intra-
cytoplasmic viral signal. 
Antibodies against myelin proteolipid protein (PLP), Nestin, Neurofilament, 
MAG, Olig1 and MBP failed to detect cellular and/or parenchymal expression in the 
brain and spinal cord of tested samples. 
No immunofluorescence was seen in sections where the primary antibody was 
omitted. 
 
Discussion 
 
This study attempted to identify specific cell populations within the CNS that 
may be infected by CVV and how these populations change during and after CVV 
infection in ovine fetuses. This study also focused on evaluating changes in residing 
CNS cell populations in response to CVV infection. The major findings were that CVV 
primarily targets neuronal cells and not glial cells and that the infection is associated 
with a severe microgliosis in the brain and spinal cord of 42 to 63 dg infected fetuses.  
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NeuN, a monoclonal antibody that detects a neuron-specific nuclear protein, has 
been previously studied and used to detect neurons in fetal and adult human and rodent 
brain,
101,125
 as well as neurons of middle to late gestation ovine fetuses.
91,135
 CVV viral 
signal was detected primarily in neurons and, rarely, was detected in the cytoplasm of 
astrocytes and Olig2-positive cells. Areas with extracellular viral signal corresponded to 
areas of necrosis and likely represent areas with breakdown of cells and release of viral 
antigen. Even though the largest amount of viral signal was detected in the cytoplasm of 
neurons, viral signal was identified in the cytoplasm of numerous cells not labeled with 
NeuN. Although these were morphologically similar to NeuN-positive cells, their 
identity remains unknown. Human fetal brain NeuN-positive cells are expressed early in 
gestation, and increased numbers are seen in different regions of the brain with the 
progression of gestation.
125
 For this reason, we believe that the NeuN-negative cells 
were likely primitive neurons or neuronal cells not expressing NeuN at the evaluated 
time points. Conceivably, these cells could represent premature glia as well. 
Ionized calcium binding adaptor molecule 1 (Iba1) is a macrophage specific 
protein, highly expressed in microglia. Iba1 genes are conserved between species, and 
identical cDNA sequences have been identified in homolog proteins AIF, MRF-1, ITR-1 
and BART-1in humans and rodents. Iba1 is expressed in resting and activated microglial 
cells.
70,86
 and injured neurons release factors that activate microglia.
140
 A significant 
microgliosis was identified in infected fetuses as early as 42 dg. The microgliosis 
observed in the brain and spinal cord of infected animals could be linked to an early fetal 
development of an immune response to viral infection. In fact, upregulation of 
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proinflammatory cytokines associated with innate immune response are observed in 
CVV-infected fetuses (shown in Chapter IV). Some of these cytokines, such as IL-1, IL-
6 and TNF-α, are known to be produced by activated microglia in response to neuronal 
injury. 
Iba1 antibodies identified microglial cells in the brain of control and infected 
animals; however, the rabbit Iba1 gave better definition of the microglial cytoplasm and 
cellular membranes. Therefore, this antibody was used for determination of microglial 
expression in the CNS. Because we were unable to do double-labeling with two 
antibodies from the same host species (the anti-CVV antibody was a polyclonal antibody 
made in rabbits), the goat Iba1 was used for double-labeling with CVV. No 
colocalization of CVV with microglial cells was detected in examined specimens. 
Microgliosis induced by neuronal damage is usually associated with astrocyte 
activation in mature brains. Activated microglial cells release proinflammatory cytokines 
that stimulate development of astrogliosis and CNS scar formation.
140,155
 In the present 
study, no significant increase in GFAP-positive cells or astrocytic processes was 
observed in infected fetuses compared to control fetuses. GFAP expression was low in 
earlier control and infected fetuses, but increased expression was noted in all fetuses at 
56 and 63 dg (21 and 28 dpi), primarily in the spinal cord. The most likely reason for the 
lack of astrogliosis in infected fetuses is the presumed immaturity of astrocytes in early 
developing fetuses. Previous studies evaluating ovine fetal brain at 60 dg identified 
GFAP-positive cells only after 80 dg.
68
 In human fetuses, low numbers of GFAP-
positive cells are identified mainly around the ventricles at/after 12 weeks of gestation, 
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which corresponds to 45 dg in ovine fetuses, even though vimentin-positive cells, 
presumed to be immature astrocytes, have been identified in 5 weeks old human 
fetuses.
144
 
Olig2 is a basic helix-loop-helix transcription factor that was initially described 
to be specific for oligodendrocytes. Further studies revealed that this transcription factor 
is expressed throughout the CNS also being expressed in neural stem cells that will 
differentiate into neurons and astrocytes.
104
 In the ventral spinal cord motor neuron 
areas, a population of Olig2-positive neural progenitor cells give rise to motor neurons 
and then to oligodendrocytes.
84
 The differentiation of Olig2-positive cells has been 
investigated.
84,85,104
 Even though complex and not completely elucidated at this point, it 
appears that Olig2-positive cells differentiation in fetuses depends on the anatomical 
location of these cells and up/downregulation of the Olig2 gene, with some Olig2-
positive neural stem cells becoming neurons, astrocytes or oligodendrocytes. In the 
forebrain, large numbers of neuron progenitors are Olig2-positive. Late Olig2-positive 
cells in the telencephalon will likely differentiate into astrocytes, whereas Olig2-positive 
cells in the diencephalon, spinal cord and hindbrain most likely give rise to 
oligodendrocytes.
85,104
 Similar studies using Olig2 have not been conducted in the brain 
of ovine fetuses during early development; however, if the known differentiation and 
distribution of Olig2-positive cells in the brain and spinal cord of fetal mice and humans 
applies in sheep, the few Olig2-positive cells with cytoplasmic viral signal identified in 
this study could be neuronal progenitor cells. This is reasonable considering that these 
Olig2-positive cells also were found in areas that have large numbers of NeuN-positive 
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cells. If some of the detected Olig2-positive cells were being programmed to develop 
into oligodendrocytes or astrocytes, that would support our conclusions that CVV does 
not target these cell lineages, as reflected by the low amount of viral signal observed in 
the cytoplasm of the differentiated cells. Further studies to determine the specific 
distribution and differentiation of these cells in the brain and spinal cord of ovine fetuses 
await new fetal markers before final conclusions can be made regarding all early targets 
of CVV.   
Several other antibodies against mature or immature oligodendrocytes (Olig1, 
MBP, MAG) were used in sections of the brain and spinal cord of ovine fetuses in this 
study in an attempt to specifically identify oligodendroglial cells. Unfortunately, the 
antibodies used failed to identify cells in the ovine fetus. Similarly, antibodies to identify 
neuronal progenitor cells (Nestin) and neuronal cells (Neurofilament) also failed to 
detect cells in the CNS of the ovine fetus. For the most part, these antibodies have not 
been tested in young ovine fetuses. Because these were developed for other species, they 
may not cross react with ovine tissues, or the cells of the immature fetuses studied here 
have not expressed the markers yet. 
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CHAPTER IV 
OVINE FETAL INNATE IMMUNE RESPONSE TO  
CACHE VALLEY VIRUS INFECTION 
 
Introduction 
 
Cache Valley virus (CVV) is a mosquito-borne bunyavirus of the family 
Bunyaviridae, Orthobunyavirus genus, Bunyamwera group,
127
 and endemic in the North 
America.
39
  Serologic studies have shown that unlike most bunyaviruses, the vectors of 
CVV also infect larger mammals with virus being isolated from sheep, cattle and horses, 
and it causes reproductive losses in small ruminants.
29-31,34,39,40,44,45
 Rarely, the virus has 
been associated with meningoencephalitis in humans.
25,128
 “In utero” ovine fetal 
infection causes abortion and fetal malformations, mainly affecting the musculoskeletal 
(MSS) and central nervous systems (CNS).
29-31,34,39,44
  
Previous studies describing and experimentally reproducing CVV-induced 
malformations in ovine fetuses showed that the development of fetal lesions depends on 
the fetal age when infected. If the virus is inoculated between 28 and 48 dg, fetal death 
and abortion or MSS and CNS malformations occur. No apparent malformations are 
observed if the virus is inoculated after 48 dg.
30,39
 Virus isolation only can be made from 
early infected fetuses, and viral recovery from tissues of term abortions and malformed 
lambs is uniformly unsuccessful. The virus is cleared from infected tissues within a few 
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weeks after infection and before the presumed age of fetal immunocompetency, at 
approximately 70-75 dg.
39,94,113,127
 
The gestation period of the ewe is approximately 145 days. Ovine fetuses develop 
erythropoiesis, myelopoiesis and megakaryopoiesis in the yolk sac and liver at 
approximately 17 dg. At approximately 20 to 25 dg, lymphocyte production begins in 
the thymus, and lymphocytes are in the bloodstream at 48-50 dg.
99
 At 45-50 dg, T and B 
lymphocytes and cells with surface immunoglobulins are seen in the spleen and lymph 
nodes.
87,88
 The lymph nodes become integrated into a lymphatic system around 65 dg.
99
 
Establishing the time when fetuses are able to respond to antigens is difficult because 
available data is based on use of assays such as serum neutralization that were 
established for use in mature animals. Additionally, gestation assay points used in 
experiments are somewhat arbitrary. Ovine fetal antibody response to viral infection at 
titers greater than 1:2 has been detected after 76-78 dg.
106
  Because the ruminant 
syndesmochorial placenta prevents passage of immunoglobulins from the ewe to the 
fetus,
145
 antibodies in fetuses and precolostral newborns are those produced by the fetus. 
For this reason, in utero viral infections can be diagnosed in aborted fetuses and stillborn 
ruminants using serum neutralization tests.  Such testing is necessary with CVV because 
the fetus clears the virus long before the end of gestation.
34,39
 
In Chapter II, it was demonstrated that fetuses infected with CVV early in 
gestation (around 35 dg) have low viral signal in tissues around 56 dg and are able to 
clear the infection before development of an adaptive immune system at 75 dg.
39
 
Similar, age-based findings have been described in Akabane virus-infected 
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fetuses.
26,94,106
 Because no effective serum neutralization antibody (an adaptive immune 
response) has been shown in ovine fetuses at the time when CVV is cleared from 
fetuses, it may be that the ovine fetus mounts an innate immune response for early viral 
clearance. To test this hypothesis, expression of selected genes associated with the innate 
immune response were compared in tissues of CVV-infected and non-infected ovine 
fetuses, and CVV viral mRNA was quantitated in selected tissues to correlate the 
measured innate response with viral clearance. In addition, fetal MX protein, an 
interferon-stimulated GTPase previously associated with antiviral activity against 
bunyaviruses,
50,66,76,124,139
 was quantitated in fetal allantoic and amniotic fluids. 
Expression of the interferon stimulated gene 15 (ISG15), that has been shown to be 
produced by fetuses in response to viral infection in utero,
27,130,134
 was evaluated in 
CVV-infected fetal tissues. Finally, distribution of B and T lymphocytes and 
immunoglobulin-positive cells was evaluated in infected and non-infected, ovine fetal 
tissues in early gestation.  
 
 Materials and methods 
 
Virus inoculation and sample harvesting  
A group of fifteen, seronegative, pregnant Rambouillet ewes were housed in BSL2 
confinement buildings according to protocols approved by The Institution Animal Use 
and Biosafety Committee. At 35 dg, ewes were inoculated in utero with a 1ml inoculum 
containing 10
5
 50% tissue culture infection doses (TCID50) of CVV (infected group) 
3
 or 
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1ml of minimum essential medium (MEM) (mock infected/control group) as previously 
described in Chapter II. The viral inoculum was derived from the second passage of an 
isolate from allantoic membrane from an experimentally infected fetus.
30
 At 7, 10, 14, 21 
and 28 dpi, three ewes (one mock-infected and two virus-infected) were humanely 
euthanized.  Selected fetal tissues and their fluids were harvested and immediately 
frozen at -80ºC or placed in an RNA stabilization solution (Ambion, Life Technologies, 
Carlsbard, CA) and frozen at -80ºC. The remaining fetal tissues and placenta were fixed 
in 4% paraformaldehyde and in Davidson’s AFA (acetic acid, formalin, alcohol) 
fixative. 
 
Real time quantitave polymerase chain reaction (qPCR) 
To quantitate relative numbers of CVV viral copies, and genes of interest, real 
time qPCR was performed on samples of brain and muscle harvested from CVV-
infected or mock-infected ovine fetuses according to a previously published protocol 
with minor modifications.
37
 Briefly, RNA was isolated from harvested samples and 
homogenized in Trizol reagent (Gibco BRL, Bethesda, MD) according to the 
manufacturer’s recommendation. In order to eliminate contamination with genomic 
DNA, the extracted RNA was treated with the DNAse1 amplification reagent 
(Invitrogen, Carlsbard, CA), and the RNA concentration was quantified by 
spectrophotometry. RNA quality was determined by denaturing samples in an agarose 
gel electrophoresis. The cDNA was synthesized from 500ng of total RNA combined 
with primer mix containing oligodT primer (0.2µg/ml), random hexamer primer (300 
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µg/ml; Invitrogen), dNTPmix (10mM each) and incubated at 65ºC for 5 min. After 
incubation, SuperScript II reverse transcriptase (Invitrogen) was added to the reaction 
according to manufacturer’s recommendations and reverse transcribed under the 
following conditions: 25°C for 10 min; 42°C for 60 min and 70ºC for 5 min. To test for 
genomic DNA contamination, control reactions were prepared without reverse 
transcriptase.  
Specific oligonucleotide primers of interest (Table 3) were obtained from Oligo 5 
program (Molecular Biology Insights, Inc) for the following genes: M segment of 
glycoprotein 1 of CVV, interferon-α (IFN-α), IFN-β, TNF-α, IL-1, IL-6, Mx1, Mx2, 
ISG15, TLR7 and TLR8. The real-time qPCR reaction was performed using the ABI 
prism 7900HT system (Applied Biosystems, Foster, CA) with power SYBR green PCR 
Master Mix (Applied Biosystems). Primer specificity and efficiency (-3.6>slope>-3.1) 
were confirmed using a test amplification run. The data was normalized using cycle 
threshold (Ct) values for the ovine glyceraldehyde 3-phosphate dehydrogenase 
(GADPH) gene in each sample. Semi quantitative analysis was calculated with the 
ΔΔCT method, and expressed as relative fold changes compared with the lowest value 
for mock-infected samples. To calculate relative amounts of viral mRNA, relative fold 
changes were compared with the infected sample with the lowest ΔΔCT. 
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Table 3. Primer sequences used for RT-qPCR 
Gene name Forward Reverse 
CVV CAC CAG CGA AAT CCC AAT CAC CA CTC CAG ACA TAG CAC CCA CCA 
TNF-α CGG CGT GGA GCT GAA AGA CAA CTG CGA GTA GAT GAG GTA AA 
IL-1 AGT GAT GGC TTG CTA CAG T CCG AGG TCC AGG TGT T 
IL-6 GAG GGA AAT CAG GAA ACT GT CTC GTT TGA GGA CTG CAT CT 
TLR7 ACT CCT TGG GGC TAG ATG GT GCT GGA GAG ATG CCT GCT AT 
TLR8 TCC ACA TCC CAG ACT TTC TA GTT CTT GTC CTC ACT CTC TT 
MX1 GTA CGA GCC GAG TTC TCC AA ATG TCC ACA GCA GGC TCT TC 
MX2 CAT CCA TAA ATC GCT CCC CTT GT GCT CCT CTG TCG CCC TCT GGT 
ISG15 TGA  CGG TGA AGA TGC TAG GG ACT GCT TCA GCT CGG ATA CC 
IFN-α ACC CAG CAC ACC TTC CAG CTC TT CCT CGC AGC CCC TCC TC 
IFN-β TGG TTC TCC TGC TGT GTT TCT C CGT TGT TGG AAT CGA AGC AA 
 
 
Protein slot blot  
The protein concentration in the allantoic and amniotic fluid was determined using 
the Bradford Assay as recommended by the manufacturer (Bio-rad Laboratories). 
According to the protein concentration, samples were prepared and diluted to 12µg of 
protein for the amniotic fluid and 50µg of protein for the allantoic fluid in a final volume 
of 200µl of Tris-Buffered saline (TBS). The volume was deposited onto a nitrocellulose 
membrane (Bio-Rad Laboratories, Richmond, CA) in a Bio-dot SF micro-ﬁltration 
apparatus (Bio-Rad Laboratories). Nonspeciﬁc binding sites were blocked by immersing 
the membrane in 5% skim milk in TBS-Tween (TBST) for 1 hour at room temperature 
on an orbital shaker. The membranes were incubated overnight at 4°C in 2.5% milk-
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TBST containing a rabbit anti-ovine Mx1 polyclonal antibody (gift from Dr. Troy Ott, 
Penn State University)
73
 at a concentration of 1:10000. The membrane was then 
incubated for 1 hour with goat anti-rabbit IgG (1:10000 dilution in 2.5% milk-TBST) 
and further incubated for 1 min with Bio-Rad chemiluminescence reagent. The 
concentration of each protein in the samples was determined quantitatively in relative 
light units using Bio-Rad chemidoc imager. 
 
Immuhistochemistry 
Immunohistochemistry was performed on 5µm, deparaffinized sections of 
paraformaldehyde-fixed tissues mounted onto positively-charged, silanized slides using 
an automated system for immunohistochemistry (DakoCytomation Autostainer®, Dako, 
Carpinteria, CA) with minor modifications to the IHC protocol described in Chapter II. 
Antigen retrieval was performed in a decloaker chamber (Biocare Medical, Concord, 
CA) with slides soaked in citrate buffer pH 6.0.  Sections were incubated with anti-
ISG15 polyclonal antibody (diluted 1:500) for 30 min (Dr. Thomas Hansen, Fort Collins, 
CO),
10
 CD3 (diluted 1:400) polyclonal antibody for 35 min (Dako), anti-CD79a 
antibody, clone JCB117 (diluted 1:200) for 30 min (Dako), anti-ovine IgG (diluted 
1:500) for 35 min and anti-ovine IgM (diluted 1:2000) for 30 min (KPL, Inc, 
Gaithersburg, MD). The primary antibody was followed by incubation with the
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secondary antibody (MACH 2
 
anti-rabbit Biocare Medical [CD3, IgG, IgM]; or 
ImmPress anti-Mouse Ig, Vector Labs [ISG15, CD79a]) for 20 min. A chromagen 
complex, 3.3-diaminobenzidine tetrachloride (DAB, Dako), was used to detect the 
targeted antigens, and sections were counterstained with hematoxylin. Slides were 
coverslipped with permount mounting solution. Tissues were evaluated to determine 
percentage of infected cells in each examined organ and graded as follows: less than 3% 
of cells positive (mild); between 3-15% of cells positive (moderate); more than 15% of 
cells positive (marked). 
 
Statistical analysis 
The quantitative data for mRNA expression and protein levels on fetal fluids were 
subjected to the Wilcoxon signed rank test to determine differences between infected 
and non-infected groups. Differences between groups at different dpi were subject to the 
one pair students t-test. In order to reduce heterogeneity between samples, the data was 
log-transformed if necessary, and p-values below 0.05% were considered statistically 
significant. The data are presented as means and overall standard error. 
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Results 
 
Real-time qPCR 
No significant difference in gene expression was observed either between infected 
animals at each different dpi or between control animals at different dg. Therefore, the 
data for each gene for each evaluated tissue was pooled into two groups: control and 
infected animals (Fig. 10). The following genes were significantly upregulated (p-value 
<0.05) in the brain and skeletal muscle of CVV-infected fetuses versus noninfected 
fetuses:  IL-1, IL-6, Mx2, ISG15, TLR7 and TLR8. Only in the brain was TNF-α 
significantly upregulated. Except for ISG15 and Mx1, significantly higher upregulation 
of these genes was observed in the brain compared to the skeletal muscle. Similarly, the 
relative number of copies of CVV was significantly higher in the brain when compared 
to the skeletal muscle (Fig. 11). Progressively lower means of relative number of copies 
of CVV were observed in both brain and skeletal muscle with the progression of the 
infection. A statistically significant difference was observed in the brain of fetuses 
between 14-28 dpi (CVV in the brain of 10dpi fetuses were excluded from analysis due 
to high variability in those samples), and in the SKM when comparing 10-14 dpi, 10-21 
dpi, and 10-28 dpi. 
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Figure 10. Relative expression of genes related with immune response in brain and 
skeletal muscle of control and CVV-infected animals. *p < 0.05, **p < 0.01, ***p < 
0.005.  
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Figure 11. Relative number of CVV viral copies in main target tissues, brain (BRA) and 
skeletal muscle (SKM) after 10, 14, 21 and 28 dpi. *p < 0.05, **p < 0.01.  
 
 
Protein slot blot 
A significant (p-value <0.01) increase in the amount of Mx1 protein in the 
allantoic and amniotic fluid was observed in infected fetuses versus non-infected fetuses 
at each time point examined (Fig. 12). Similar to the quantitative data collected with the 
real time qPCR, no effect of day or interaction of day versus infection was seen in 
evaluated samples. 
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Figure 12. Amount of ovine Mx1 protein in allantoic and amniotic fluid in control and 
infected animals. p < 0.005 
 
 
Immunohistochemistry for ISG15 
ISG15 was detected in several tissues of all infected fetuses, but no ISG15 
immunolabeling was observed in control fetuses (Fig. 13). In infected fetuses, a strong 
signal was observed in numerous cells of the cerebral parenchyma and meninges, and 
fewer cell numbers were positive in the spinal cord.  Most fetuses at 7-21dpi had marked 
ISG15 signal in the brain, with moderate signal observed at 28 dpi. The ISG15 signal in 
the spinal cord of infected fetuses varied between mild to moderate at all test points. 
Multifocal clusters of cells with positive immunolabeling were observed in the SKM of 
infected fetuses through 21 dpi with only rare cells with positive signal at 28 dpi. Other 
1 
  
65 
6
5
 
tissues with clusters of cells with positive signal included: heart, smooth muscle of 
intestine, tongue, fibroblasts in the subcutaneous tissue, wall of large arteries, around 
small vessels, spleen (one fetus at 21dpi), and rarely in the lungs, tonsils and thymus of 
earlier infected fetuses. 
 
 
Figure 13. Immunohistochemistry for ISG15 in brain and skeletal muscle. A rabbit 
polyclonal antibody against ovine ISG15 protein was stained with DAB chromagen 
(brown) on the brain (A,B,C) and skeletal muscle (D,E,F) from 45 dg control fetuses 
(A,D) and from infected fetuses at 14 dpi (45 dg) (B,E) and 28 dpi (63 dg) (C,F). 
Numerous cells in the brain and skeletal muscle of infected fetuses are positive for 
ISG15. No positive cells were observed in tissues of control fetuses. 
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Immunohistochemistry of B and T lymphocytes, IgG and IgM 
 At 7 dpi/42 dg, scattered CD79a positive cells were observed in the dorsal 
abdominal cellular lymphoid aggregates around the abdominal aorta, which correspond 
to sites of development of rudimentary renal or mesenteric lymph nodes, and rarely in 
the hepatic sinusoids in both control and infected animals. At 10 dpi/45 dg, slightly 
increased numbers of CD79a, IgG and IgM-positive cells were observed in the same 
locations in infected and control animals (Fig. 14, A-C). Rare IgM-positive cells were 
observed in the meninges of one infected animal. At 14 dpi/49 dg, slightly increased 
numbers of CD79a, IgG and IgM-positive cells were observed in the sites described 
above, and at this timepoint, CD79a and IgM-positive cells were in the spleen of one of 
the infected animals (Fig. 14, D-F). Surprisingly, another infected animal also had a 
marked infiltration of CD79a, IgG and IgM-positive cells in the meninges of the brain 
and spinal cord and in rare cells within the parenchyma (Fig. 14, G-I). Increased 
numbers of CD79a, IgG and IgM-positive cells were arranged around splenic arterioles 
in both infected and control animals at 21 dpi/56 dg and 28 dpi/63 dg, besides also being 
in the previously described sites. Numerous IgG and IgM-positive cells were observed in 
the meninges of the spinal cord of two infected fetuses at 21 dpi, and rare 
immunoglobulin-positive cells were observed in one fetus at 28 dpi. Moderate to marked 
numbers of CD3 positive cells, evaluated only in sections of brain and transversal 
sections of the abdomen including the lumbar spinal cord of control and infected fetuses 
at 21 and 28 dpi, were detected in the spleen, renal and mesenteric lymph nodes in all 
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fetuses. Scattered CD3 positive cells were in the meninges of the BRA and SPC of one 
infected fetus at 14dpi and in the meninges of the SPC in one fetus at 21 dpi. 
 
 
Figure 14. Immunohistochemistry for B cells, plasma cells and ovine IgG and IgM in 
lymph node, spleen and brain. A polyclonal antibody against B cells and plasma cells 
(CD79a), ovine IgG and ovine IgM was stained with DAB chromagen (brown). CD79a 
(A), IgG (B) and IgM (C) positive cells were observed in rudimentary lymph nodes at 
42-45dg in control fetuses. CD79a (D), IgG (E) and IgM (F) positive cells were 
observed in the spleen of infected fetuses. A remarkable number of CD79a (G), IgG (H) 
and IgM (I) positive cells were seen in the leptomeninges of an infected fetus at 14 dpi. 
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Discussion 
 
Ovine fetuses are able to mount an immune response associated with CVV 
infection earlier in gestation than previously described.
64,94,106,113
 Although the fetal 
immune response was not able to completely clear virus by the end of the study, at 63 
dg, as shown in Chapter II, infected ovine fetuses were able to reduce the viral load from 
the CNS and MKS, tissues targeted by CVV. Viral signal was also markedly reduced or 
absent in the ganglion, retina, kidney and heart. 
As shown in Chapter II, CVV targets mainly cells within the CNS and 
musculoskeletal system, and viral signal was markedly reduced in the brain and almost 
completely cleared in the skeletal muscle after 21-28 dpi in fetuses infected at 35 dg. 
Similarly, a progressive reduction in viral load, as shown by mean relative amounts of 
viral copies was observed in the brain and SKM in this study, with significant 
differences observed between most days of infection in the SKM, and in the brain 
between 14 and 28 dpi. In addition, the numbers of relative viral copies in the brain were 
significantly higher than in the skeletal muscle.  
The Mx protein, an interferon stimulated GTPase involved in intracellular 
trafficking, membrane remodeling and fusion processes, is capable of restricting growth 
of viruses, including influenza virus, measles virus and bunyaviruses within the 
orthobunyavirus, phlebovirus and hantavirus genuses.
50,58-61,66,76,77,139
 In viral infections, 
the Mx protein acts by interfering with transport of viral components in infected cells. In 
a model proposed by Haller and Kochs (2002),
59
 MxA forms large, membrane-
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associated self-assemblies that store monomers of this protein. With infection, 
monomers bind to viral target structures, forming new assemblies involving viral 
intermediates that lead to mislocalization of viral components and consequent viral 
replication inhibition.
59
 Human MxA has been shown to inhibit replication of La Crosse 
virus by binding to the viral nucleocapsid protein, and forming large copolymers that 
accumulate in the perinuclear region.
76
 Previous studies have demonstrated antiviral 
activity of bovine Mx2 in cattle infected with BVDV.
62,130
 Because Mx has a 
demonstrated antiviral effect against bunyaviruses, this study measured expression of the 
Mx molecule in infected tissues. A significant upregulation of ovine Mx1 and Mx2 was 
observed in evaluated tissues from infected fetuses. Increased secretion of Mx1 was 
identified in fetal fluids in infected ovine fetuses. Thus, this protein reasonably could 
contribute to clearance of CVV infection. 
Another gene that was significantly upregulated in both brain and skeletal muscle 
and highly expressed in tissues in infected animals was ISG15. Similar to the Mx 
protein, ISG15 is induced by type I interferon, and has been associated with antiviral 
activity.
134
 In recent studies, ISG15 has been shown to conjugate to proteins in a manner 
similar to ubiquitin.
4,156
 Modifications and interference of antiviral signaling pathways 
involving ISG15 are mechanisms used by Crimean-Congo hemorrhagic fever virus, a 
bunyavirus, to evade the innate immune response.
4
 Upregulation of numerous ISG, 
including ISG15, and continuous stimulation of the innate antiviral response has been 
demonstrated in blood and tissues of bovine fetuses and cattle infected with BVDV.
62,130
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No significant difference was observed in the expression of selected sequences of 
type I interferon genes, despite the fact that the interferon induced genes, ISG15 and 
ovine Mx1 and Mx2, were markedly upregulated in infected fetuses. Previous studies 
have demonstrated that ovine fetuses within the second and third trimester of gestation 
are able to produce levels of interferon similar or greater to those produced by adult 
animals in response to a viral infection.
121
 Since type I interferon induced genes were 
upregulated, it is presumed that type I interferon genes were upregulated at some time 
point, and due to its short half-life, upregulation was not detected at the time points 
evaluated. Even though less likely, one may have to consider the possibility of both 
ISG15 and ovine Mx being upregulated by an interferon-independent pathway or that the 
selected sequences amplified in this study were not representative of the type I interferon 
production status in infected fetuses.  
CD79a-positive cells (B lymphocytes and plasma cells) were observed in the 
spleen of CVV-infected fetuses at 49 dg. This is similar to results in previous studies, 
that have identified B lymphocytes in ovine fetal lymph nodes and spleen as early as 47-
48 dg.
87,88,114
 Both infected and non-infected fetuses had scattered CD79a-positive, IgM 
and IgG-positive cells in lymphoid aggregates in the dorsal aspect of the abdominal 
cavity, sites of development of rudimentary renal and/or mesenteric lymph nodes, as 
early as 42 and 45 dg, respectively. The identification of CD79a-positive cells in 
regional lymph nodes earlier than observed in the fetal spleen, supports the previously 
proposed idea that extrasplenic sites have the potential of producing B lymphocytes,
7,114
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and potentially explains the fact that splenectomized fetuses are also capable of 
colonizing Peyer’s patches with B lymphocytes.114,115  
Besides the presence of CD79a, IgM and IgG-positive cells in the spleen and 
lymph nodes of both infected and non-infected fetuses, a marked infiltration of CD79a, 
IgM and IgG-positive cells was also observed within the meninges with fewer cells 
within the parenchyma of the brain and spinal cord of infected fetuses at 49 dg. It 
appears that the ovine fetus not only mounts an innate immune response to a viral 
infection, but is also able to stimulate an adaptive immune response. Unfortunately, 
blood samples were not available from the fetuses during these experiments and fetal 
neutralizing antibodies could not be assayed. In ovine fetuses infected with Akabane 
virus, the earliest day of gestation where IgM and IgG-positive cells were observed in 
tissues was 59-60 days gestation. Titers >1:4 were detected only after 100 dg.
70,149
 Two 
other studies detected neutralizing antibodies after 76-78 dg, with titers ranging from 8-
64 in one of these studies.
94,106
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CHAPTER V 
SUMMARY AND CONCLUSIONS 
 
CVV is a viral pathogen with a tropism for the ovine fetal CNS, skeletal muscle 
and fetal membranes. The study of early infection demonstrated a tropism that correlated 
well with the CNS and musculoskeletal malformations observed in spontaneous CVV 
disease. With CVV, the development of arthrogryposis probably has a multifactorial 
pathogenesis involving effects on developing neurons, myocytes, and fetal membranes 
(Fig. 15). CVV is the only viral infection shown to cause oligohydramnios. The virus is 
cleared from most infected fetal tissues by approximately 65 dg, before the presently 
accepted onset of ovine immunocompetence. 
In the CNS of ovine fetuses, CVV targets primarily fetal neurons and rarely glial 
cells. The viral infection is associated with and presumably induces a marked 
microgliosis in fetuses; however, astrocytosis is not identified. The fetus is able to mount 
an immune response associated with CVV infection earlier in gestation by upregulating 
genes that participate in innate immune response. Possibly the intense microgliosis in the 
brain is an attempt of the fetus to control the virus infection, by releasing antiviral 
cytokines that contribute to viral clearance in the CNS. The infected fetus upregulates 
Mx genes that have been shown to restrict growth of bunyaviruses. In addition, cells of 
the adaptive immune response, CD79a-positive, IgM and IgG-positive cells, are found in 
large numbers in early infected tissues and also could contribute to viral clearance.  
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Future studies should evaluate even earlier dpi to determine which tissues are 
initially infected and how does the virus spreads to all infected tissues. The features that 
control the intravenous route of inoculation and role of mosquito effector molecules in 
the natural route of inoculation of CVV in ovine fetuses.  
Furthermore, studies should be conducted to better understand the functional 
development of innate and adaptive immune response in ovine fetuses exposed to CVV 
and to other viral infections. For example, to better understand the role of Mx in viral 
clearance, an Mx knockout mouse model could be tested to evaluate if Mx is indeed a 
key player in innate immunity against CVV. In addition, future studies should determine 
the specificity of early CD3, CD79a, IgG and IgM-positive cells in infected tissues 
Finally, the ovine fetus infected with CVV is a model for development of CNS 
and MSK fetal malformations and oligohydramnios.     
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Figure 15.  Proposed pathogenesis of CVV infection in the ovine fetus.  CVV infects the 
fetal membranes (A), which results in oligohydramnios (B’) and subsequent fetal 
akinesia. After penetrating fetal membranes, CVV infects fetal target tissues (B”), 
mainly the CNS and SKM. The infection of the fetal membranes, CNS and SKM results 
in fetal malformations (C). The fetus stimulates the innate immune response (D) as well 
as the adaptive immune response by producing antibodies (E) which will further result in 
viral clearance from infected tissues (F).   
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APPENDIX A 
 
List of antibodies  
Antibody Application Host Catalog # Concentration 
CD3 T lymphocytes Rabbit 
Dako: 
A045201 
1:400 
CD79a B Lymphocytes Mouse 
Dako: 
M705001 
1:200 
CVV CVV antigen Rabbit -- 1:300 
GFAP Astrocytes Mouse 
Millipore: 
MAB360 
1:300 
Iba1 
Microglia and 
macrophages 
Rabbit 
Wako: 
019-19741 
1:500 
Iba1 
Microglia and 
macrophages 
Goat Abcam: ab5076 1:300 
IgG Ovine IgG Rabbit 
KPL: 
01-23-02 
1:500 
IgM Ovine IgM Rabbit 
KPL: 
01-23-03 
1:2000 
ISG15 ISG15 Mouse 
Gift from Dr. 
Hansen 
1:500 
MAG Mature oligodendrocytes Hamster Gift from Dr. Li 1:1 
MBP Mature oligodendrocytes Rat 
Millipore: 
MAB386 
1:100 
Nestin Neuron progenitor cells Rat 
Millipore: 
MAB353 
1:200 
NeuN Differentiated neurons Mouse 
Millipore: MAB 
377 
1:80 
Neurofilament Axons Mouse 
Covance: SMI-
31R 
1:200 
Olig1 Oligodendrocyte lineage Mouse 
Millipore: 
MAB5540 
1:100 
Olig2 
Neural progenitor cells 
and mature 
oligodendrocytes 
Rabbit 
Millipore: 
MAB9610 
1:100 
PLP Mature oligodendrocytes Rat Gift from Dr. Li 1:500 
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